DESIGN OF A 24-WEEK TRIAL OF EMPAGLIFLOZIN ONCE DAILY IN HYPERTENSIVE BLACK/AFRICAN AMERICAN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
AACE ePoster Library. Ferdinand K. 05/27/16; 131472; 292
Keith Ferdinand
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Rate & Comment (0)
{{ help_message }}
{{filter}}